TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00842205
Drug: pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peg-IFN alfa 2a 180ug s.c. QW or peg-IFN alfa 2b 1.5 ug/kg s.c. QW
Study: NCT00842205
Drug: Ribavarin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ribavirin 1000-1200mg p.o. daily 48weeks or ribavirin 100-1200mg p.o. daily 48 weeks
Study: NCT04194645
Drug: BI 474121 tablet
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 474121 tablet
Study: NCT04194645
Drug: BI 474121 oral solution
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 474121 oral solution
Study: NCT00706589
Drug: aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial dose : 2mg, Maximum dose : 20mg
Study: NCT03140787
Drug: Nasal Spray of Lidocaine HCL
Normalized name: lidocaine Mucosal Spray
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This spray consists of lidocaine hydrochloride-epinephrine hydrochloride
Study: NCT03140787
Drug: Infiltration injection of Lidocaine HCL
Normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is the ordinary method of establishing anesthesia for patients undergoing dental treatment for caries.
Study: NCT01632657
Drug: Sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single subcutaneous injection sumatriptan 6mg (in 0.5ml) in recovery
Study: NCT01098487
Drug: Eltrombopag olamine
Normalized name: Eltrombopag Olamine
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Thrombopoietin receptor agonist
Study: NCT02928445
Drug: RVT-101 35 mg
Normalized name: RVT-801
DrugBank: ACG-801 (DB17659)
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily, oral, 35-mg tablets
Study: NCT02928445
Drug: RVT-101 70 mg
Normalized name: RVT-801
DrugBank: ACG-801 (DB17659)
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily, oral, 35-mg tablets
Study: NCT00117832
Drug: Azelastine nasal spray
Normalized name: azelastine Nasal Spray
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03834454
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
Study: NCT03834454
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7.5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
Study: NCT02793505
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: This is not an intervention but an observed exposure.
Study: NCT03328975
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The overall purpose of this study is to evaluate the effect of a corticosteroid shoulder injection on glucose levels in insulin-dependent diabetic men and women.
Study: NCT01130597
Drug: patiromer
Normalized name: Patiromer
DrugBank: Patiromer (DB09263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active investigational drug
Study: NCT03571334
Drug: IncobotulinumtoxinA (Xeomin®, Merz) (INA)
Normalized name: incobotulinumtoxinA Injection [Xeomin]
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: IncobotulinumtoxinA (Xeomin®, Merz) (INA) will be reconstituted with preservative-free normal saline to a dilution of 5mL:100 units. Study participants will receive 50u INA (total volume 2.5mL) injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.) Study participants will receive one series of injections during the trial. In the hands, INA will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). In the feet, INA will be injected across the dorsal surface of the foot in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). Injections will be performed intradermally using a 5/16-inch, 32-g needle
Study: NCT00003117
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003117
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03862690
Drug: BIAsp 30
Normalized name: Fiasp
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive commercially available BIAsp 30 once daily (QD), twice daily (BID) or thrice daily (TID) for 24 weeks according to routine clinical practice. The physician will determine the starting dose and any potential later change to the dose. The decision to switch the patient to NovoMix® 30 is at the treating physician's discretion and independent from the decision to include the patient in the study.
Study: NCT02088684
Drug: fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant will be supplied according to local practice and regulation. Fulvestrant is a commercially available product, comes in 500 mg dose and is an injection for intramuscular (i.m.) administration.
Study: NCT02074579
Drug: TU-100
Normalized name: TU-100
DrugBank: TU-100 (DB12467)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15g daily, orally as 5g three times daily for 4 consecutive weeks
Study: NCT00267332
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02473159
Drug: indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
Study: NCT01457859
Drug: Triclosan
Normalized name: Triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triclosan coated surgical sewing threads (VICRYL+ and MONOCRYL+) applied for leg wound closure after CABG
Study: NCT00077337
Drug: romidepsin
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01778088
Drug: I-131-CLR1404 Injection
Normalized name: I-131-CLR1404
DrugBank: Iopofosine I-131 (DB15244)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00952237
Drug: GM-CSF
Normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF (Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor) The dose and duration of GM-CSF (7.5 mcg/kg/day) was selected. If used alone, this dose and duration would result in effective mobilization. GM-CSF will be started on Day #7 and will continue until completion of leukapheresis.~G-CSF will be started (5mcg/kg/d) on Day #7 and will be given each morning. G-CSF will continue until completion of leukapheresis.
Study: NCT00952237
Drug: IL-2
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 dose escalation: IL-2 will be administered as a single daily subcutaneous injection each evening until completion of leukapheresis.~Escalation of the dose of IL-2 will be performed using the below schema with the following levels. Patients will be started on Level 1. (Level 0 is included since, if toxicity is meet in Level 1, the dose will be decreased to Level 0).~Level 0 - 3 x 105 i.u./m2/day for 11 days Level 1 - 6 x 105 i.u./m2/day for 11 days Level 2 - 1 x 106 i.u. /m2/day for 11 days as above Level 3 - 1.5 x 106 i.u. /m2/day for 11 days as above Level 4 - 2 x 106 i.u. /m2/day for 11 days as above
Study: NCT00123851
Drug: Tarceva (OSI-774)
Normalized name: Tarceva
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00123851
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00392262
Drug: valsartan + amlodipine
Normalized name: amlodipine / valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01694576
Drug: Adjuvant chemotherapy with paclitaxel and nedaplatin
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients receive 3 cycles of adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation
Study: NCT01079962
Drug: Bisoprolol
Normalized name: Bisoprolol
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bisoprolol tablet will be administered orally at a dose of 5 milligram (mg) once daily in the morning for 12 weeks.
Study: NCT01079962
Drug: Atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol tablet will be administered orally at a dose of 50 mg once daily in the morning for 12 weeks.
Study: NCT02399839
Drug: lomitapide
Normalized name: Lomitapide
DrugBank: Lomitapide (DB08827)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As prescribed by Physician.
Study: NCT04527354
Drug: Treamid
Normalized name: Treamid
DrugBank: Treamid (DB16365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Treamid 50 mg once a day during 4 weeks
Study: NCT01810042
Drug: ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.5mg of ranibizumab is injected into the vitreous cavity through pars plana.
Study: NCT02164513
Drug: fluticasone furoate (FF)
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FF will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg and FF/VI 100 mcg/25 mcg
Study: NCT02164513
Drug: vilanterol (VI)
Normalized name: Vilanterol
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VI will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, FF/VI 100 mcg/25 mcg and UMEC/VI 62.5 mcg/25 mcg
Study: NCT02164513
Drug: umeclidinium bromide (UMEC)
DrugBank: Clidinium (DB00771)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: UMEC will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, and UMEC/VI 62.5 mcg/25 mcg
Study: NCT03571620
Drug: Q301 Cream
Normalized name: CREAM
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.0% or 1.4% Q301 Cream
Study: NCT02197039
Drug: esomeprazole or pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis is achieved spontaneously or by gastroscopy. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Because of concern for patient safety with certain drug-drug interactions, patients who take clopidogrel receive intravenous pantoprazole (Pantoloc®, Takeda, Singen, Germany), including an 80 mg loading dose and a 3-day continuous high-dose (8 mg/h) of infusion.
Study: NCT01546454
Drug: leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single 22.5 mg subcutaneous depot suspension
Study: NCT01546454
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 to 100 mg vaginal suppositories twice daily for 13 days
Study: NCT01051947
Drug: Nebivolol
Normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg by mouth daily for 2 weeks 20 mg by mouth daily for 2 weeks 40 mg by mouth daily for 2 weeks
Study: NCT01051947
Drug: Metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dosage prescribed prior to starting on study
Study: NCT00125515
Drug: Memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One arm receives 30 mg bid and the other arm receives receives 15mg bid
Study: NCT00125515
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received the equivalent of 50 mg/day. Dispensed as 100 mg on Mondays and Wednesdays and 150 mg on Fridays.
Study: NCT02647827
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral metformin 500 mg three times daily, in total 1500 mg per day. To reduce gastrointestinal side-effects of metformin, the dose will be slowly escalated starting with 500 mg daily during the first week, increasing to 500 mg twice per day during the second the week, and 500 mg three times daily, morning, lunch and dinner from the third week in total 16 weeks including the 3 weeks step-up phase (i.e. 4 months).
Study: NCT00952731
Drug: afimoxifene
Normalized name: Afimoxifene
DrugBank: Afimoxifene (DB04468)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2mg/breast applied daily in the form of a gel for 4-10 weeks.
Study: NCT00952731
Drug: tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules) for 4-10 weeks.
Study: NCT00999427
Drug: Povidone-iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine 10% solution. A piece of 10x10 cm gauze soaked in Povidone-iodine 10% solution wrapped around the index finger of the examiner is inserted into the rectum of the subject in arm A. This gauze will be wiped back and forth across the prostate with the finger at least five times from one lateral margin of the prostate gland to the other. The examiner will allow at least 2 minutes to elapse between antisepsis and the insertion of the first needle into the prostate in order to allow the Povidone-iodine to dry.
Study: NCT00135863
Drug: tinzaparin
Normalized name: Tinzaparin
DrugBank: Tinzaparin (DB06822)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01329900
Drug: Ofatumumab
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1000 mg by vein on Day 1 and 2000 mg by vein on Day 8
Study: NCT01329900
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3.33 gm/m2 by vein on Days 2, 3, and 4 continuously.
Study: NCT01329900
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 mg/m2 by vein over 2 hours every 12 hours Days 2, 3, and 4 for 6 doses.
Study: NCT01329900
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 gm/m2 by vein over 1 hour on Day 2 (given before Ifosfamide starts)~2.66 gm/m2/day by vein continuous infusion given over 24 hours daily for 3 days starting on Day 2 (together with Ifosfamide)~After Ifosfamide/Mesna, 2 gm/m2 by vein given over 12 hours for one dose.
Study: NCT01329900
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 6 mcg/kg subcutaneously twice a day on day 6 (rounded off to the nearest vial) until completion of apheresis.
Study: NCT02167854
Drug: TRASTUZUMAB
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02682927
Drug: ZX008 (Fenfluramine Hydrochloride)
Normalized name: fenfluramine hydrochloride
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5. The product is sugar free and is intended to be compatible with a ketogenic diet.
Study: NCT01893346
Drug: CAZ-AVI
Normalized name: CAZ
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single IV dose of Ceftazidime and Avibactam. Dosage regimen will vary depending on cohort.
Study: NCT03132779
Drug: Intralipid
Normalized name: Intralipid
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adose of intralipid given and rechecking NKcells activity
Study: NCT00701961
Drug: Mefloquine-artesunate
Normalized name: artesunate and mefloquine
DrugBank: Mefloquine (DB00358)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefloquine-artesunate fixed dose combination comprised of 100 mg of artesunate and 220mg of mefloquine per tablet, developed by DNDi and manufactured by farmanguinhos (Brazil).
Study: NCT01178528
Drug: ivabradine
Normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 7.5 mg bd
Study: NCT01178528
Drug: Drug:Carvedilol and Drug:Ivabradine
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: up to 12.5/5 mg bd
Study: NCT01178528
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg bd
Study: NCT01621477
Drug: clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given on Day -9 and Day -8 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
Study: NCT01621477
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given on Day -9 and Day -8 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
Study: NCT01621477
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given on Day -7 and Day -6 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
Study: NCT01621477
Drug: Plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given on Day -7 and Day -6 (Day 0 is first stem cell infusion). Drug class: Hematopoietic Stem Cell Mobilizer
Study: NCT01621477
Drug: antithymocyte globulin (rabbit)
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given on Day -4, Day -3, Day -2, and Day -1 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
Study: NCT01621477
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given on Day +11 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
Study: NCT01621477
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given on Day +11 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
Study: NCT02851745
Drug: Linagliptin
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01877382
Drug: Milademetan
Normalized name: Milademetan
DrugBank: Milademetan (DB15257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-3032b will be administered as an oral capsule. It will be supplied in 5, 20, 80, and/or 200 mg capsules individually packaged in desiccant-embedded aluminum blisters.
Study: NCT01877382
Drug: Milademetan
Normalized name: Milademetan
DrugBank: Milademetan (DB15257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milademetan will be administered as a single oral capsule or as a combination of multiple oral capsules containing 5, 20, 80, and/or 200 mg. An alternate combination of 30 and/or 100 mg capsules of milademetan may be utilized.
Study: NCT00217737
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01904734
Drug: Clomiphene
Normalized name: Clomiphene
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Start with 25 mg and escalate to 50 mg in men not achieving goal for serum testosterone after 3 weeks
Study: NCT04392427
Drug: Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Target population: any subject with COVID-19 PCR positive pharyngeal swab and referred to the above-mentioned quarantine without any comorbidities and no sensitivity or contraindication to the three drugs.~* Sample size: will depends on sequential analysis until a significant effect will be detected with a maximum of 100 subjects in each arm.~* Randomization: subjects will be allocated to either arm by block randomization method with sealed opaque envelops. Each block will include 10 subjects (to be allocated randomly as 5 in each group)~* Intervention:~A) Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days
Study: NCT00224289
Drug: Latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost 0.005% ophthalmic solution QHS 8 weeks
Study: NCT03361774
Drug: Dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 ppm fluoride).
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be instructed to dose the toothbrush with a strip of dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 ppm fluoride) (a full brush head) and brush for at least 1 timed minute, twice daily (morning and evening), making sure to brush all sensitive areas of their teeth.~Participants will be permitted to rinse with tap water post-brushing if they wish to.
Study: NCT03361774
Drug: Dentifrice containing 0.454% w/w SnF2 (1100 ppm fluoride).
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be instructed to dose the toothbrush with a strip of dentifrice containing 0.454% w/w SnF2 (1100 ppm fluoride) (a full brush head) and brush for at least 1 timed minute, twice daily (morning and evening), making sure to brush all sensitive areas of their teeth. Participants will be permitted to rinse with tap water post-brushing if they wish to.
Study: NCT01467986
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmacotherapeutic Group: protein kinase inhibitor ATC-Code: L01XE06 Excipients: Tablet core: Lactose monohydrate, Cellulose, microcrystalline, Croscarmellose sodium, Hydroxypropyl cellulose, Magnesium stearate. Film-coating: Hypromellose, Titanium dioxide, Macrogol 400 Formulation: film coated tablet Route of Administration: orally. Patients should be instructed to swallow the tablets as a whole and not to split, chew, or crush them.